PATH has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of UiPath from a hold rating to a sell rating in a report on Tuesday, December 14th. Berenberg Bank upgraded shares of UiPath from a hold rating to a buy rating and set a $64.00 price target for the company in a report on Thursday, December 9th. Morgan Stanley upgraded shares of UiPath from an equal weight rating to an overweight rating and set a $74.00 price target for the company in a report on Friday, December 3rd. KeyCorp dropped their target price on shares of UiPath from $86.00 to $69.00 and set an overweight rating for the company in a report on Thursday, December 9th. They noted that the move was a valuation call. Finally, Cleveland Research assumed coverage on shares of UiPath in a report on Monday, November 29th. They issued a neutral rating for the company. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and a consensus target price of $67.82.
PATH opened at $36.73 on Wednesday. The company’s 50 day simple moving average is $46.03 and its two-hundred day simple moving average is $54.09. UiPath has a 1-year low of $35.61 and a 1-year high of $90.00.
In other news, EVP Ted Kummert sold 155,318 shares of UiPath stock in a transaction on Friday, December 10th. The shares were sold at an average price of $43.74, for a total transaction of $6,793,609.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $56.48, for a total transaction of $2,259,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 616,060 shares of company stock valued at $30,091,295. Corporate insiders own 28.60% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Arkadios Wealth Advisors purchased a new stake in UiPath in the third quarter valued at $109,000. Jasper Ridge Partners L.P. purchased a new stake in UiPath in the second quarter valued at $1,021,000. Blueshift Asset Management LLC acquired a new position in UiPath in the second quarter valued at $217,000. Greenspring Associates LLC acquired a new position in UiPath in the second quarter valued at $125,139,000. Finally, DekaBank Deutsche Girozentrale increased its stake in UiPath by 2,705.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 547,141 shares of the healthcare company’s stock valued at $28,850,000 after purchasing an additional 527,641 shares during the period. 46.54% of the stock is owned by hedge funds and other institutional investors.
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows.
See Also: What is an economic bubble?
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.